Advances in Trichomonas vaginalis Diagnostics and Research Barbara Van Der Pol, PhD, MPH University of Alabama at Birmingham School of Medicine.

Slides:



Advertisements
Similar presentations
Appraising a diagnostic test study using a critical appraisal checklist Mahilum-Tapay L, et al. New point of care Chlamydia Rapid Test – bridging the gap.
Advertisements

RESULTS: After Discordant Analysis RESULTS: Discordant Testing
Analytical Sensitivity of the Urine-Based APTIMA® Trichomonas vaginalis molecular assay using the automated Tigris® Platform A.H. Freeman1, M.W. Pandori2,
John Harrison, Michelle Garassi, Sara Wierzbicki, William LeBar Hospital Consolidated Laboratories-Providence Hospital, Southfield, MI, Evaluation of the.
Number of specimens tested
PREVALENCE OF CHLAMYDIA TRACHOMATIS, NEISSERIA GONORRHOEAE AND TRICHOMONAS VAGINALIS IN YOUNG WOMEN IN KENYA USING THE GEN-PROBE APTIMA ASSAYS J Moncada.
Figure 1. Trichomonas Assay Procedure
Global Consultation on the Implementation of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB M. Akhalaia, MD, Microbiologist, Reference.
Recommendations for STD Clinical Preventive Services for Persons Living with HIV/AIDS.
Screening Recommendations
S L I D E 0 Sexually Transmitted Infections in adolescents Deepa Camenga, MD, MHS, FAAP Instructor of pediatrics, adolescent medicine Yale School of Medicine.
Feasibility of STD Control for HIV Prevention: Findings from Three Southern Cities NEW ORLEANS: Thomas Farley & Deborah Cohen BALTIMORE: Anne Rompalo,
Printed by Comparison of Primary Care and Clinical Laboratory Methods for the Diagnosis of Bacterial Vaginosis and Yeast Vaginitis.
CDC National Infertility Prevention Project Laboratory Update Region I Wells Beach, Maine June 1-3, 2009 Richard Steece, Ph.D., D(ABMM)
Region I Advisory Board Meeting Wells Beach, ME June 9, 2008 Use and Verification of STD Nucleic Acid Amplification Tests for non-FDA Cleared Clinical.
Curable versus incurable STDs. Objectives To describe the natural history and epidemiology of two curable STDs (i.e. syphilis and chlamydia) and two non-
2014 PATIENT HISTORY How would you diagnose and screen Miranda? How would you treat Miranda? Are there any additional steps you would take? Antimicrobial.
The laboratory investigation of urinary tract infections
Risk factors for Incident Trichomonas vaginalis among Women Recruited in RESPECT-2, an HIV Prevention Trial D Helms 1, D Mosure 1, T Peterman 1, C Metcalf.
Distribution of Trichomonas vaginalis Among Women at High Risk for HIV Infection Barbara Van Der Pol, James Williams, Jacquelyn Murphy and the Project.
Kees Rietmeijer, MD, PhD Denver Prevention Training Center 1.
Chlamydia trachomatis testing Research Center for Genetic Engineering and Biotechnology “Georgi D. Efremov”, MASA What is Chlamydia trachomatis? Chlamydia.
Use of an Internet-Based Self-Screening Program to Screen for Chlamydia and Gonorrhea Wendy Voet On Behalf Of Charlotte A. Gaydos and Karen Dwyer, Mathilda.
What are STD’s or STI’s? Sexually Transmitted Disease Sexually Transmitted Infection Diseases that are transmitted through all types of sexual activity.
STD 2014.
Faiza Ali MD, Ericka Hayes MD, Gaurav Kaushik MPH, Nicole Carr RN, Katie Plax MD Washington University School Of Medicine Department of Pediatrics.
Region I Laboratory Update CDC National Infertility Prevention Project Boston, Massachusetts November 15, 2010 Richard Steece, Ph.D., D(ABMM) Laboratory.
HPI A 23 year-old female comes to your office complaining of vaginal discharge, itching, and burning with urination for several days. The symptoms had.
Findings from the Male Urethral Microbiome Project Barbara Van Der Pol, PhD, MPH (HPER) David E Nelson, PhD (Biology)
Increasing the Efficiency of STI Clinics by Tailoring Services Based on a Risk Triage System Julie A. Subiadur, BSN, CCRC BC Brandy Mitchell, RN Dean McEwen.
SSuN Cycle 2 SSuN Part B Laboratory Component: Trichomonas Resistance Evaluation Bob Kirkcaldy, Lori Newman, Kristen Mahle December 4, 2008.
PID Normal Human Fallopian Tube Tissue C. trachomatis Infection (PID)
A collaborative journey down the rabbit hole Barbara Van Der Pol, PhD, MPH (HPER) David E Nelson, PhD (Biology)
Bob Kirkcaldy, Nicholas Gaffga, Lori Newman
High prevalence rate of Trichomoniasis Vaginalis in an urban HIV clinic Debbie Mohammed, DrPH, MS, MPH, AACRN Prerak Shukla, MBBS Maria Szabela, MD Jihad.
Sexually Transmitted Infections. What is an STI? Sexually transmitted infections are infections passed from person to person through sexual contact.
Prevalence of Chlamydia and Gonorrhea Among Patients With Genital Ulcer Disease in Zimbabwe: Potential Implications for Syndromic Management More Mungati:
Trichomonas vaginalis
NAAT identified chlamydial infections: Enhanced sensitivity, reduced transmissibility? Presenter: Maria Villarroel, MA Authors: Maria A. Villarroel, MA.
The Dublin Well Woman Centre and The National Virus Reference Laboratory  Approved by ICGP Ethics Committee.
The Changing Paradigms of Who, Where, and How to Screen for Chlamydia Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases Johns.
Evaluation of 5 different tests for Trichomonas vaginalis infection and cost effective planning for clinical implementation B. Nathan 1, J Appiah 2, D.
Gabriella Bathgate, Melissa Perry, John White
Sexually Transmitted Infections in Pregnancy Jeffrey Klausner, MD, MPH Professor of Medicine and Public Health Attending Physician Ronald Reagan Medical.
CHLAMYDIA TRACHOMATIS – DIAGNOSIS AND MANAGEMENT Jess Gaddie (adapted from presentation by Rachel Coyne)
High prevalence of chlamydia, gonorrhoea, mycoplasma and trichomonas in FSW reached at their working place in Germany Klaus Jansen, PhD , IUSTI.
100% Ciprofloxacin resistance in gonococcal isolates in patients with or at high risk of HIV acquisition in an urban Ugandan clinic DR EMILY MABONGA KING’S.
Mayuri Dasari M.D. Cook County Loyola Provident
What’s New in STI Testing?
Vaginal Swabs Clinical Information Why? Murray Robinson
Trichomonas Vaginalis
SEXUALLY TRANSMITTED INFECTIONS
Sexually Transmitted Infections
Molecular detection and prevalence of mycoplasmas, ureaplasmas and Chlamydia trachomatis in human urogenital tract – cross-sectional study Sittová M.1.
Prevalence of Sexually Transmitted Infections and Bacterial Vaginosis among Female Adolescents in the United States: Data from the National Health and.
TRICHOMONAS VAGINALIS.
A qPCR assay that simultaneously detects Mycoplasma genitalium and mutations associated with macrolide resistance Litty Tan Director of Research & Development.
Modern diagnosis of Trichomonas vaginalis infection
Appraising a diagnostic test study using a critical appraisal checklist Mahilum-Tapay L, et al. New point of care Chlamydia Rapid Test – bridging the gap.
What are Sexually Transmitted Diseases (STDs)?
Chlamydial and Gonococcal Infections
A study of high risk African American women, 15 to 21 years of age
Sexually Transimitted Diseases
Richard Steece, Ph.D., D(ABMM)
Appraising a diagnostic test study using a critical appraisal checklist Mahilum-Tapay L, et al. New point of care Chlamydia Rapid Test – bridging the gap.
Acute HIV Infection and PrEP: Opportunities and challenges
Sexually Transmitted Infections (STIs)
The Chain of Infection and Sexually Transmitted Diseases
Reproductive Systems Mini REVIEW
Nucleic Acid Amplification Tests for the Diagnosis of Chlamydia trachomatis Rectal Infections Bachmann LH1,2, Johnson R3, Cheng H1, Markowitz L3, Papp.
Presentation transcript:

Advances in Trichomonas vaginalis Diagnostics and Research Barbara Van Der Pol, PhD, MPH University of Alabama at Birmingham School of Medicine

Disclosures  Honorarium, Speaking Fees or Research Support  Atlas Genetics  BD Diagnostics  Beckman Coulter  Cepheid  Great Basin Scientific  Hologic  Rheonix  Roche Molecular Diagnostics

Topics  Why test for Trich?  How should we test?  What’s on the way?

Background  2012 WHO estimates of incident STI in 2008  Chlamydia105.7 million4.1% ↑  Gonorrhea106.1 million21.0% ↑  Trichomonas276.4 million11.2% ↑

Regional variation in Trichomonas prevalence Newman L, et al. PLoS One, 2015

STI rates in the US

AWARE Study findings  Women attending 9 STD clinics in the US  Baseline and 6 month f/u  Of 245 (14.6%) positive at baseline, only 177 would have been tested by wet prep  109 were positive at 6 mo  Previous TV positive was the largest single risk factor RR 3.37 ( ), p<.001 Alcaide ML, et al. STI 2016

Meta-Analyses of Pre-term Birth Outcomes Silver, BJ et. al. STD 2014

Effect of TV infection on risk of HIV acquisition By 30 mo, risk increases from 4%  17% P=.036 Mavedzenge SN, et al. STD, 2010

Effect of HIV infection on risk of acquiring TV infection By 30 mo, risk increases from 11%  24% P=.001 Mavedzenge SN, et al. STD, 2010

 Clinical manifestations  Wet prep microscopy  Rapid tests  Laboratory tests  Culture  Nucleic acid probe  Nucleic acid amplification What are the options?

 Discharge may be confused with other vaginal disturbances  Co-infections are common  pH is not reliable  Strawberry cervix is clear, but not common  Sensitivity - unknown Clinical Manifestations

Microscopy  Sensitivity – 50-60%

 Immunochromatographic  OSOM ® sensitivity – 80-90% Rapid tests

Culture  Sensitivity:60-75%  Time to results: 3-7 days

 Hologic Aptima TV assay detects rRNA  High throughput  BD TV Q x DNA-based assay  High throughput  BD MAX CT/GC/TV  Low-medium throughput  Cepheid Xpert TV DNA-based assay  Throughput depends on size of system purchased Nucleic Acid Amplification Tests

 Can be performed with sample used for CT/GC  Urine, vaginal and endocervical  Can detect nucleic acid in asymptomatic women  40-50% of infections may be asymptomatic! Advantages of NAAT

Comparison of diagnostic assays AssayEquipmentSample TypesNotes MicroscopyMicroscopeVag swabRequires motility and a clean microscope OSOMNoneVag swabCLIA waived so true POC Affirm VPIIIAffirm VPIII instrument Vag swabSymptomatic patients only; lab- based AmpliVueAmpliVue instrument Vag swabLab-based CultureIncubator; microscope Vag swab, urine sediment Lab-based XpertXpert instrument Vag or cervical swab; urine Lab-based TVQ x MAX BD Viper BD MAX Vag or cervical swab; urine High-complexity Aptima TVTigris or Panther Vag or cervical swab; urine High-complexity Adapted from Van Der Pol. J Clin Microbiol, 2016

Comparison (continued) AssayTime to resultCo-testingSensitivityCost Microscopy<5 minBV+$ OSOM15 minnone+++$$ Affirm VPIII<1 hBV++$$ AmpliVue<1 hnone++$$ Culture1-7 daysnone++$$ Xpert90 minCT/GC++++$$$$ TVQ x MAX <6 hCT/GC++++$$$ Aptima TV<6 hCT/GC++++$$$ Adapted from Van Der Pol. J Clin Microbiol, 2016

Assays on the near horizon  Instrument-dependent triplex NAATs  ~30 min to results  Instrument-free POC assays (mostly TV only)  Antigen capture LFA  NAATs  Disposable test materials  reduces costs  increases accessibility

Resistance?  Treatment failure that suggests resistance occurs  Reduced in vitro metronidazole susceptibility  Occurs in ~5-10% of isolates tested in the US  Does not correlate well with clinical outcomes  May be a function of the presence/absence of the TV virus and/or Mycoplasma hominis  Data from da Luz Becker (Infection, Genetics & Evolution, 2015) do not support this hypothesis  However, strain type may play a role in this association

Other aspects to think about  Infertility  Associations with tubal factor infertility  Associations with atypical spermatozoa and seminal fluid properties supported by in vitro studies  Cervical Neoplasia?  Pathogenesis mechanisms exist  Association with HPV persistence has been shown  Prostate disorders?  BPH  Prostate cancer

Rethinking the TV Diagnostics  Prevalence & long-term sequelae suggest TV control is warranted in some settings  Screening, regardless of symptoms makes sense in some settings  Wet prep is great as a primary screening tool  Some POC are useful if affordable  Treating partners is likely important

Thank You! Questions?